At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NXGL NEXGEL, INC.
Trading 11-26 14:05:10 EST
3.26
-0.11
-3.26%
High3.48
Low3.25
Vol36.39K
Open3.43
D1 Closing3.37
Amplitude6.82%
Mkt Cap22.14M
Tradable Cap18.05M
Total Shares6.79M
T/O123.36K
T/O Rate0.66%
Tradable Shares5.54M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Winter Conference on December 10-11, 2024
NEXGEL Preliminary Revenue For Q3 2024 Of ~$2.85M, An Increase Of ~133% YoY, As Well As An Increase Of ~30% Over The Company's Previously Issued July Q3 Revenue Guidance Of $2.20M
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name. It is also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.